Working with Umeå University and GE Healthcare, CELLINK will help develop a transplantable skin construct to give burn patients a better quality of life.
Traditionally, patients with severe burns have received keratinocyte-based epidermal sheet transplants. However, these transplants cannot replace sweat glands, nerves or vasculature, leaving patients far from cured. Patients need to moisturize twice daily and stay inside when it’s too warm, and they experience additional pain and itching with no treatment option but to reduce overall activity.
CELLINK is combining expertise with Umeå University and GE Healthcare to develop alternative transplants that promote nerve regeneration and reduce patient suffering at the source. The new transplants will contain sebaceous glands or the types of cells that can regenerate dermal layers, nerves and vasculature, providing an innovative solution to improve patients’ quality of life.
The project will be conducted through collaborations with burn centers in Norway, Finland, Denmark and the Netherlands, and the researchers aim to begin treating patients in 2020.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected].